readthroughSign in
Nov 12, 2026Exchange listing

Rani Therapeutics shifts Nasdaq listing to Capital Market, gets more time on bid price

Nasdaq granted Rani an additional 180 days, until May 10, 2027, to regain compliance with the $1.00 minimum bid price rule after transferring its listing.

Rani Therapeutics Holdings disclosed in an 8-K filing that on November 10, 2026, it received written notice from Nasdaq that the exchange had approved the company's application to transfer the listing of its Class A common stock from The Nasdaq Global Market to The Nasdaq Capital Market and had granted an additional 180 calendar days, or until May 10, 2027, to regain compliance with the Minimum Bid Price Requirement.1 The transfer took effect at the opening of business on November 12, 20261, and the company's Class A common stock will continue to trade under the symbol "RANI."1

The underlying issue dates back to May 11, 2026, when Rani received a letter from Nasdaq notifying the company that, based on the closing bid price of its Class A common stock for the preceding 30 consecutive business days, it was not in compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum closing bid price of $1.00 per share.1 The company had initially been given 180 calendar days, or until November 9, 2026, to regain compliance with the Minimum Bid Price Requirement.1

According to the notice, Rani was eligible for the additional compliance period because it met the applicable market value of publicly held shares requirement for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market, other than the Minimum Bid Price Requirement, and provided written notice of its intention to cure the deficiency, including by effecting a reverse stock split, if necessary.1

To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days at any time during the additional 180-day compliance period1, though Nasdaq may, in its discretion, require a longer period, generally not exceeding 20 consecutive business days, before determining compliance has been regained.1 The filing states there can be no assurance that the company will regain compliance with the Minimum Bid Price Requirement during the additional compliance period or otherwise maintain compliance with the other continued listing requirements of The Nasdaq Capital Market.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.